Sumatriptan Injection Reduces Productivity Loss During a Migraine Attack

Abstract

Objective: To evaluate the impact of sumatriptan succinate injection compared with placebo on productivity loss during a migraine attack in the workplace.

The global burden of migraine

“…A number of long-term studies have examined the impact of migraine and benefits of treatment on workplace and non-workplace productivity [59]. Sumatriptan was demonstrated to reduce migraine-associated productivity loss during a minimum 8-hour work shift by approximately 50% compared with placebo, alleviating headache in more S9 than three-fourths of subjects in the work-place [60]. A prospective sequential multinational (5-country) study evaluated the effects of subcutaneous sumatriptan on HRQoL [61].…”

Sumatriptan (Subcutaneous Route of Administration) for Acute Migraine Attacks in Adults

“…The response of headaches to study treatment was measured using a standard fourpoint pain intensity scale in all 35 studies. The majority of the studies (27/35) reported at least one IHS-preferred outcome (IHS 2000); seven studies (Akpunonu 1995;Cady 1998;Jensen 1995;Russell 1994;S2BS78;Thomson 1993;Visser 1992) provided data for secondary outcomes only. Just over half of the studies (19/35) offered participants the option of a second dose of study medication if either the initial response had been inadequate, or if the participant experienced recurrence (defined as a relapse of moderate or severe intensity headache after an initial response), (13 studies), or to treat recurrence alone (six studies).…”

“…• Sumatriptan 6 mg versus placebo (Akpunonu 1995;Bates 1994;Bousser 1993;Cady 1991 Study 1 and Study 2;Cady 1993;Cady 1998;Dahlof 1998;Diener 1999;Diener 2001;Facchinetti 1995;Ferrari 1991;Gross 1994;Henry 1993;Jensen 1995;Mathew 1992;Mushet 1996 • Sumatriptan 6 mg versus subcutaneous naratriptan 0.5 mg (Dahlof 1998). …”

“…We considered no studies to be at high risk of bias from random sequence generation, allocation concealment, or blinding. Fifteen studies (Akpunonu 1995;Bates 1994;Bousser 1993;Cady 1993;Dahlof 1992;Dahlof 1998;Diener 1999;Gross 1994;Henry 1993;Mathew 1992;Mushet 1996 Study 1 and Study 2;Sang 2004;Schulman 2000;Thomson 1993) did not include 50 or more participants in each treatment arm and we therefore considered them to be at high risk of bias from their size.…”

“…Sumatriptan 6 mg versus placebo: Five studies (987 participants) provided data for the use of rescue medication up to 24 hours after initial dosing (Cady 1998;Dahlof 1998;Diener 1999;Diener 2001;Schulman 2000).…”